Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 2, 2012, Pages 187-198

  Brown, Ashley ^a   Goodman, Zachary ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

adefovir; chronic hepatitis B; cirrhosis; entecavir; fibrosis; hepatitis B virus; lamivudine; telbivudine; tenofovir

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PLACEBO; TELBIVUDINE; TENOFOVIR;

DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIMIT OF DETECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LONG TERM CARE; POLYMERASE CHAIN REACTION; PROGNOSIS; REMISSION; REVIEW; STELLATE CELL;

ANIMALS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; NUCLEOSIDES; NUCLEOTIDES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84858068082     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.4     Document Type: Review

References (67)

1. European Association for The Study of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis. Br. J. Hepatol. 50(2), 227-242 (2009).
2. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol. Int. 2, 538-549 (2008).
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50(3), 661-662 (2009).
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 48(2), 335-352 (2008).
5. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21(1), 77-82 (1995).
6. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 26(5), 1338-1342 (1997). (Pubitemid 27509322)
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006). (Pubitemid 44307383)
8. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006). (Pubitemid 43042691)
9. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3), 678-686 (2006). (Pubitemid 43374518)
10. Iloeje UH, Yang HI, Jen CL et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin. Gastroenterol. Hepatol. 5(8), 921-931 (2007). (Pubitemid 47161142)
11. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 101(8), 1797-1803 (2006). (Pubitemid 44166589)
12. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 19(6), 670-675 (2004). (Pubitemid 38858201)
13. Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J. Natl Cancer Inst. 97(4), 265-272 (2005).
14. Yuan HJ, Yuen MF, Ka-Ho WD, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J. Viral Hepatol. 12(4), 373-379 (2005). (Pubitemid 40961476)
15. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology 37(6), 1309-1319 (2003). (Pubitemid 36667310)
16. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351(15), 1521-1531 (2004).
17. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 115(2), 209-218 (2005). (Pubitemid 40385459)
18. Friedman SL. Liver fibrosis - from bench to bedside. J. Hepatol. 38(Suppl1), S38-S53 (2003).
19. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 134(6), 1655-1669 (2008). (Pubitemid 351615417)
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2), 289-293 (1996). (Pubitemid 26260021)
21. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol. 47(4), 598-607 (2007). (Pubitemid 47331757)
22. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1(5), 431-435 (1981). (Pubitemid 12218164)
23. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22(6), 696-699 (1995).
24. Calvaruso V, Burroughs AK, Standish R et al. Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49(4), 1236-1244 (2009).
25. Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis. Hepatology 45(4), 886-894 (2007). (Pubitemid 46631557)
26. McHutchison J, Goodman Z, Patel K et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 138(4), 1365-1373 (2010).
27. Manousou P, Dhillon AP, Isgro G et al. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl. 17(2), 178-188 (2011).
28. Boursier J, de Ledinghen V, Zarski JP et al. A new combination of blood test and fibroscan for accurate noninvasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am. J. Gastroenterol. 106(7), 1255-1263 (2011).
29. Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin. Chim. Acta 411(1-2), 86-91 (2010).
30. Cales P, Boursier J, Oberti F et al. FibroMeters: A family of blood tests for liver fibrosis. Gastroenterol. Clin. Biol. 32(6 Suppl1), 40-51 (2008).
31. Smith JO, Sterling RK. Systematic review: noninvasive methods of fibrosis analysis in chronic hepatitis C. Aliment. Pharmacol. Ther. 30(6), 557-576 (2009).
32. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39(6), 1647-1654 (2004). (Pubitemid 38702666)
33. Falize L, Guillygomarc'h A, Perrin M et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases. Hepatology 44(2), 472-477 (2006). (Pubitemid 44214887)
34. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122(5), 1303-1313 (2002). (Pubitemid 34465173)
35. Maylin S, Martinot-Peignoux M, Moucari R et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135(3), 821-829 (2008).
36. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341(17), 1256-1263 (1999). (Pubitemid 29489740)
37. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339(2), 61-68 (1998). (Pubitemid 28304879)
38. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29(3), 889-896 (1999). (Pubitemid 29109606)
39. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124(1), 105-117 (2003). (Pubitemid 36055344)
40. Rizzetto M, Tassopoulos NC, Goldin RD et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis. Br. J. Hepatol. 42(2), 173-179 (2005). (Pubitemid 40143462)
41. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348(9), 800-807 (2003). (Pubitemid 36245756)
42. Marcellin P, Chang TT, Lim SG et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348(9), 808-816 (2003). (Pubitemid 36245757)
43. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovirdipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48(3), 750-758 (2008).
44. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovirdipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131(6), 1743-1751 (2006). (Pubitemid 44958517)
45. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357(25), 2576-2588 (2007). (Pubitemid 350294224)
46. Hou J, Xu D, Shi G et al. Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammation and fibrosis regression in patients with chonic hepatitis B. J. Hepatol. 54, S287 (2011).
47. Liaw YF, Gane E, Leung N et al. 2-year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136(2), 486-495 (2009).
48. Zeuzem S, Gane E, Liaw YF et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis. Br. J. Hepatol. 51(1), 11-20 (2009).
49. Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40(4), 883-891 (2004). (Pubitemid 39288121)
50. Di Marco V, Di Stefano R, Ferraro D et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir. Ther. 10(3), 431-439 (2005). (Pubitemid 41151021)
51. Yuen MF, Seto WK, Chow DH et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 12(8), 1295-1303 (2007).
52. Tenney DJ, Pokornoski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J. Hepatol. 50(Suppl1), S10 (2009).
53. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354(10), 1001-1010 (2006). (Pubitemid 43357804)
54. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011-1020 (2006). (Pubitemid 43357805)
55. Liaw YF, Raptopoulou-Gigi M, Cheinquer H et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 54(1), 91-100 (2011).
56. Chang TT, Lai CL, Kew YS et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51(2), 422-430 (2010).
57. Chang TT, Liaw YF, Wu SS et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3), 886-893 (2010).
58. Schiff E, Lee SS, Chao YC et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 9, 274-276 (2011).
59. Yokosuka O, Takaguchi K, Fujioka S et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J. Hepatol. 52(6), 791-799 (2010).
60. Heathcote EJ, Marcellin P, Buti M et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140(1), 132-143 (2011).
61. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359(23), 2442-2455 (2008).
62. MarcellinP, Buti M, Gane EJ et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 54(Suppl1), Abstract 1375 (2011).
63. Boyd A, Lasnier E, Molina JM et al. Liver fibrosis changes in HIV-HBV-coinfected patients: Clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir. Ther. 15(7), 963-974 (2010).
64. Boursier J, Bacq Y, Halfon P et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 21(1), 28-38 (2009).
65. Liaw YF, Sheen IS, Lee CM et al. Tenofovirdisoproxilfumarate (TDF), entracitabine/TDF, ndentecavirin patients with decompensated chronic hepatitis B liver disease. Hepatology 53(1), 62-72 (2011).
66. Manolakopoulos S, Triantos C, Theodoropoulos J et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J. Hepatol. 51(3), 468-474 (2009).
67. Pozzi M, Pizzala DP, Maldini FF, Doretti A, Ratti L. Portal pressure reduction after entecavir treatment in compensated HBV cirrhosis. Hepatogastroenterology 56(89), 231-235 (2009).